What Is Genomic High-Risk Myeloma?

被引：1

作者：

Davies, Faith E. ^{[1
]}

Walker, Brian A. ^{[2
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA

[2] Indiana Univ, Div Hematol Oncol, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA

来源：

HEMATO | 2022年 / 3卷 / 02期

关键词：

genomics; high-risk; myeloma; INTERNATIONAL STAGING SYSTEM; HEAVY-CHAIN GENE; MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATIONS; ABNORMALITIES; DYSREGULATION; SURVIVAL; DELETION; IMPACT; PROGRESSION;

D O I：

10.3390/hemato3020021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although treatment of multiple myeloma has changed dramatically over time, there is still a subpopulation of patients who do not respond to treatments and are labeled as high risk. A combination of serum and genomic markers can be used to identify and stratify these patients according to associations with outcome. The most common method of identifying the genomic markers of high-risk multiple myeloma is using fluorescence in situ hybridization using probes to identify IgH translocations or copy number changes including the t(4;14), t(14;16), t(14;20), gain 1q, and del(17p). However, as research studies utilize newer technologies, such as whole genome sequencing, more high-risk factors are being identified including mutations of TP53, DIS3, BRAF, and complex structural events. Integration of comprehensive genomic studies into clinical trials will aid in defining the genomic high-risk landscape of multiple myeloma, which in turn can be transferred to individual patient diagnostics and treatment management.

引用

页码：287 / 297

页数：11

共 77 条

[1] A simple additive staging system for newly diagnosed multiple myeloma [J].

Abdallah, Nadine H. ;

Binder, Moritz ;

Rajkumar, S. Vincent ;

Greipp, Patricia T. ;

Kapoor, Prashant ;

Dispenzieri, Angela ;

Gertz, Morie A. ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie L. ;

Hobbs, Miriam A. ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem A. ;

Kyle, Robert A. ;

Bergsagel, P. Leif ;

Fonseca, Rafael ;

Ketterling, Rhett P. ;

Kumar, Shaji K. .

BLOOD CANCER JOURNAL, 2022, 12 (01)

[2] Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma [J].

Affer, M. ;

Chesi, M. ;

Chen, W. D. ;

Keats, J. J. ;

Demchenko, Y. N. ;

Tamizhmani, K. ;

Garbitt, V. M. ;

Riggs, D. L. ;

Brents, L. A. ;

Roschke, A. V. ;

Van Wier, S. ;

Fonseca, R. ;

Bergsagel, P. L. ;

Kuehl, W. M. .

LEUKEMIA, 2014, 28 (08) :1725-1735

[3]

Avet-Loiseau H, 1999, GENE CHROMOSOME CANC, V24, P9, DOI 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO

[4]

2-K

[5] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[6] Multiple myeloma immunoglobulin lambda translocations portend poor prognosis [J].

Barwick, Benjamin G. ;

Neri, Paola ;

Bahlis, Nizar J. ;

Nooka, Ajay K. ;

Dhodapkar, Madhav, V ;

Jaye, David L. ;

Hofmeister, Craig C. ;

Kaufman, Jonathan L. ;

Gupta, Vikas A. ;

Auclair, Daniel ;

Keats, Jonathan J. ;

Lonial, Sagar ;

Vertino, Paula M. ;

Boise, Lawrence H. .

NATURE COMMUNICATIONS, 2019, 10 (1)

[7] Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma [J].

Bergsagel, PL ;

Kuehl, WM .

IMMUNOLOGICAL REVIEWS, 2003, 194 (01) :96-104

[8] Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma [J].

Bergsagel, PL ;

Chesi, M ;

Nardini, E ;

Brents, LA ;

Kirby, SL ;

Kuehl, WM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13931-13936

[9] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].

Boyd, K. D. ;

Ross, F. M. ;

Chiecchio, L. ;

Dagrada, G. P. ;

Konn, Z. J. ;

Tapper, W. J. ;

Walker, B. A. ;

Wardell, C. P. ;

Gregory, W. M. ;

Szubert, A. J. ;

Bell, S. E. ;

Child, J. A. ;

Jackson, G. H. ;

Davies, F. E. ;

Morgan, G. J. .

LEUKEMIA, 2012, 26 (02) :349-355

[10] Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups [J].

Boyle, Eileen M. ;

Rosenthal, Adam ;

Ghamlouch, Hussein ;

Wang, Yan ;

Farmer, Phillip ;

Rutherford, Michael ;

Ashby, Cody ;

Bauer, Michael ;

Johnson, Sarah K. ;

Wardell, Christopher P. ;

Wang, Yubao ;

Hoering, Antje ;

Schinke, Carolina ;

Thanendrarajan, Sharmilan ;

Zangari, Maurizio ;

Barlogie, Bart ;

Dhodapkar, Madhav V. ;

Davies, Faith E. ;

Morgan, Gareth J. ;

van Rhee, Frits ;

Walker, Brian A. .

LEUKEMIA, 2022, 36 (02) :591-595

← 1 2 3 4 5 6 7 8 →